Savara Inc. Reports $29.6 Million Net Loss in Q3 2025, Increased Operating Expenses

Savara Inc. reported a net loss of $29.6 million for the third quarter of 2025, compared to a loss of $24.2 million in the same period of 2024, reflecting a 22% increase in losses year-over-year. For the nine months ending September 30, 2025, the company recorded a net loss of $86.6 million, up from $66.8 million in the prior year. The increase in losses is attributed to higher operating expenses, which rose to $30.3 million for the quarter and $90.1 million for the nine months, driven primarily by increased research and development costs associated with the development of its investigational inhaled biologic, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis.

In terms of financial position, Savara's total assets decreased to $140.9 million as of September 30, 2025, down from $212.9 million at the end of 2024. This decline was largely due to a significant reduction in short-term investments, which fell from $181.2 million to $108.1 million. The company's cash and cash equivalents increased slightly to $16.3 million, up from $15.1 million at the end of 2024. The accumulated deficit also widened to approximately $575.9 million, reflecting the ongoing investment in research and development without any product revenue generated to date.

Strategically, Savara has focused on advancing its clinical programs, particularly MOLBREEVI, which is currently in Phase 3 development. The company has received various designations from regulatory agencies, including Fast Track and Breakthrough Therapy Designations from the FDA. However, it faced a setback in May 2025 when it received a Refusal to File letter from the FDA regarding its Biologics License Application (BLA). The company plans to resubmit the BLA in December 2025 and is actively preparing for a potential commercial launch.

Operationally, Savara's research and development expenses for the nine months ended September 30, 2025, increased by 10.5% to $60.5 million, driven by costs related to chemistry, manufacturing, and regulatory affairs. General and administrative expenses surged by 71.8% to $29.5 million, reflecting the hiring of additional personnel and increased commercial activities. The company also reported a decrease in other income, primarily due to lower interest income and a loss on extinguishment of debt.

Looking ahead, Savara's financial outlook remains contingent on the successful development and regulatory approval of MOLBREEVI. The company recently completed a public offering that raised approximately $140 million, which it intends to use for ongoing clinical development and commercialization efforts. However, Savara acknowledges the need for additional capital to sustain its operations and continue its development programs, emphasizing the uncertainty surrounding future funding and the potential impact on its long-term plans.